JAHA:能量饮料可影响健康人群的心电图参数和血压

2019-05-30 不详 MedSci原创

能量饮料可增加急诊的发病率和死亡率,本研究的目的旨在评估能量饮料对健康年轻人的心电图参数和血压的影响。本次随机双盲对照试验纳入了34名健康参与者(平均年龄22.1±3.0岁),参与者随机分成能量饮料A组、能量饮料B组和安慰剂组。主要终点事件是QTc间期,次要终点事件是QT间期、PR间期、QRS持续时间、心率和血压。能量饮料干预与时间的交互作用与校正后的QT间期明显相关,与PR间期、QRS持续时间、

能量饮料可增加急诊的发病率和死亡率,本研究的目的旨在评估能量饮料对健康年轻人的心电图参数和血压的影响。

本次随机双盲对照试验纳入了34名健康参与者(平均年龄22.1±3.0岁),参与者随机分成能量饮料A组、能量饮料B组和安慰剂组。主要终点事件是QTc间期,次要终点事件是QT间期、PR间期、QRS持续时间、心率和血压。能量饮料干预与时间的交互作用与校正后的QT间期明显相关,与PR间期、QRS持续时间、心率、收缩压和舒张压均相关(P<0.001)。从基线到随访末校正后的QT间期变化的最大值在A组、B组和安慰剂组中分别是+17.9±13.9、+19.6±15.8和+11.9±11.1 ms。另外,与安慰剂组相比,A、B组对象的外周和中央血压也明显不同。

研究结果显示,能量饮料可以明显延长QT间期和升高血压

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1911128, encodeId=6cce191112858, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Sep 12 03:52:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268154, encodeId=2ade12681540c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jun 01 02:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628745, encodeId=64671628e454d, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Jun 01 02:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367055, encodeId=88ce36e0556d, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 31 13:16:10 CST 2019, time=2019-05-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1911128, encodeId=6cce191112858, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Sep 12 03:52:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268154, encodeId=2ade12681540c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jun 01 02:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628745, encodeId=64671628e454d, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Jun 01 02:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367055, encodeId=88ce36e0556d, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 31 13:16:10 CST 2019, time=2019-05-31, status=1, ipAttribution=)]
    2019-06-01 zhaohui6731
  3. [GetPortalCommentsPageByObjectIdResponse(id=1911128, encodeId=6cce191112858, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Sep 12 03:52:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268154, encodeId=2ade12681540c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jun 01 02:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628745, encodeId=64671628e454d, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Jun 01 02:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367055, encodeId=88ce36e0556d, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 31 13:16:10 CST 2019, time=2019-05-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1911128, encodeId=6cce191112858, content=<a href='/topic/show?id=8c0d2e73196' target=_blank style='color:#2F92EE;'>#健康人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27731, encryptionId=8c0d2e73196, topicName=健康人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55f6293, createdName=lishizhe, createdTime=Thu Sep 12 03:52:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268154, encodeId=2ade12681540c, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jun 01 02:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628745, encodeId=64671628e454d, content=<a href='/topic/show?id=718f8429e5e' target=_blank style='color:#2F92EE;'>#能量饮料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84297, encryptionId=718f8429e5e, topicName=能量饮料)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df221187157, createdName=zhixianchen, createdTime=Sat Jun 01 02:52:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367055, encodeId=88ce36e0556d, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri May 31 13:16:10 CST 2019, time=2019-05-31, status=1, ipAttribution=)]
    2019-05-31 1ddf0692m34(暂无匿称)

    学习了,长知识

    0

相关资讯

盘点:JACC五月第四期研究一览

1.一种有效的继发性二尖瓣反流评估方法

JACC:过高的肺动脉高压诊断标准与死亡率增高相关

越来越多的证据表明现有的肺动脉高压(PHT)诊断标准低估了PHT的预后影响。本研究的目的旨在一个澳大利亚人群队列中评估升高的PHT对预后的影响。本研究对157842名研究对象进行了右室收缩压(eRVSP)的检测,并随访其远期预后。该队列包含74405名男性和83437名女性,平均年龄为65.6±17.7岁,最终,根据eRVSP,有17955名(11.4%)、7016名(4.4%)和4515名(2.

JACC:紫杉醇的暴露不会增加药物洗脱球囊术后的死亡风险

五年的临床试验结果肯定了紫杉醇洗脱球囊(DCB)在治疗股动脉疾病中的安全性和有效性,但近期的一项紫杉醇洗脱球囊和支架的荟萃分析认为其可增加患者的死亡率,并且紫杉醇的剂量与死亡率的风险呈相关性。本研究的目的旨在评估紫杉醇的暴露量与患者死亡率的相关性。本研究纳入了1837名紫杉醇DCB患者和143名无涂层经皮腔内血管成形术(PTA)患者,根据紫杉醇的剂量,将患者分为低剂量、中等剂量和高剂量组,三组的平

JACC:一种可以治疗肺动脉高压的疫苗研发

肺动脉高压(PAH)是一种致死性的慢性疾病,而其治疗方法尚不理想。疫苗的预防接种为PAH的治疗带来了新希望。本研究的目的旨在寻找一种可以抑制内皮素-1(ET-1)受体A型(ETAR)的疫苗以治疗PAH。本研究研发了一种特异性结合ETAR细胞外抗原表位ETR-002的抗体,并对该抗体对Ca2+信号通路的影响进行了检测。在体内,本研究将ETRQβ-002疫苗接种至野百合碱(MCT)和缺氧诱导的PAH动

JACC:雷帕霉素可减少心脏移植术后肿瘤发生率

恶性肿瘤是心脏移植后的主要死亡原因,雷帕霉素(SRL)作为抗增殖药物是心脏移植后需长期服用的药物,可能降低患者的死亡率。本研究的目的旨在评估基于钙调神经磷酸酶抑制剂(CNI)的免疫抑制(IS)转变为基于SRL的IS是否能降低心脏移植后的恶性肿瘤发生率。本研究纳入了1994-2016接受有心脏移植的523名患者,主要终点事件包括新发恶性肿瘤的发生、移植后淋巴增生性疾病(PTLD)。最终,共有307名

罗沙司他心血管安全性获权威数据验证,百亿美元EPO市场受冲击!

肾性贫血用药市场变局加深。近日,全球首个口服低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)——罗沙司他(商品名:爱瑞卓)的一项针对欧美更广泛人群的全球III期临床研究结果公示,其心血管安全性得到验证。作为阿斯利康、珐博进共同开发的全球新药,罗沙司他已于2018年12月在国内获批用于慢性肾脏病透析患者的贫血治疗,包括血液透析和腹膜透析患者。据统计,我国终末期肾病(俗称尿毒症)患者人数为200万